Misra Sanjay, Gyamlani Geeta, Swaminathan Sundararaman, Buehrig Christopher K, Bjarnason Haraldur, McKusick Michael A, Andrews James C, Johnson C Michael, Fervenza Fernando C, Leung Nelson
Department of Radiology, Mayo Clinic Rochester, 200 First St SW, Rochester, MN 55905, USA.
J Vasc Interv Radiol. 2008 Apr;19(4):546-51. doi: 10.1016/j.jvir.2007.12.447.
To evaluate the safety and tissue acquisition with transjugular renal biopsy (TJRB) by using the Quick-Core method in patients who were at high risk for complications with percutaneous renal biopsy.
This was a retrospective study, and indication for the transjugular route, complications, clinical and laboratory data, and adequacy of samples were abstracted from patient records. TJRB was performed when the patient had thrombocytopenia or coagulopathy and was at high risk for bleeding from percutaneous renal biopsy. Follow-up images were available in 25 patients; nine underwent abdominal ultrasonography (US) and 17 underwent computed tomography (CT) (one patient underwent both US and CT). The hemoglobin level, prothrombin time, international normalized ratio (INR), partial thromboplastin time, platelet count, and serum creatinine level were obtained before and after biopsy, and these findings were correlated with clinical outcomes.
Thirty-nine patients underwent 39 TJRB procedures and comprise the current study population. The procedure was technically successful in 38 of the 39 patients (97%). Twenty-four of 39 patients (63%) had a platelet count of less than or equal to 75 x 10(9)/L, 11 (29%) had an elevated INR of more than 1.4, and seven received therapeutic anticoagulation. Patients with a platelet count of less than or equal to 75 x 10(9)/L or those with an elevated INR of more than 1.4 after transfusion were not at increased risk of hematoma formation (P = not statistically significant). The mean serum creatinine level at biopsy was 283 mumol/L +/- 150. A mean of 1.8 cores +/- 1.1 were obtained, with 5.0 glomeruli +/- 3.8, 2.1 glomeruli +/- 2.8, and 2.4 glomeruli +/- 3 at light, immunofluorescence, and electron microscopy, respectively. The renal tissue was sufficient for diagnosis in 92% of patients. Major complications occurred in one patient (2.6%). Minor complications-primarily renal hematoma-occurred in 52% of the patients. Contrast medium-induced nephropathy occurred in three patients (7.8%), two of whom also had renal hematomas.
TJRB is a relatively safe and effective diagnostic tool in high-risk patients with coagulopathy and thrombocytopenia who require renal tissue for accurate diagnosis.
通过使用Quick-Core方法对经皮肾活检并发症高风险患者进行经颈静脉肾活检(TJRB),以评估其安全性和组织获取情况。
这是一项回顾性研究,经颈静脉途径的指征、并发症、临床和实验室数据以及样本充足性均从患者记录中提取。当患者存在血小板减少症或凝血功能障碍且经皮肾活检出血风险高时,进行TJRB。25例患者有随访影像资料;9例行腹部超声(US)检查,17例行计算机断层扫描(CT)检查(1例患者同时接受了US和CT检查)。在活检前后获取血红蛋白水平、凝血酶原时间、国际标准化比值(INR)、活化部分凝血活酶时间、血小板计数和血清肌酐水平,并将这些结果与临床结局相关联。
39例患者接受了39次TJRB操作,构成了当前的研究人群。39例患者中有38例(97%)操作在技术上成功。39例患者中有24例(63%)血小板计数小于或等于75×10⁹/L,11例(29%)INR升高超过1.4,7例接受了治疗性抗凝。血小板计数小于或等于75×10⁹/L的患者或输血后INR升高超过1.4的患者血肿形成风险未增加(P = 无统计学意义)。活检时平均血清肌酐水平为283μmol/L±150。平均获取1.8条组织芯±1.1条,光镜、免疫荧光和电镜下分别有5.0个肾小球±3.8个、2.1个肾小球±2.8个和2.4个肾小球±3个。92%的患者肾组织足以用于诊断。1例患者(2.6%)发生了严重并发症。52%的患者发生了轻微并发症,主要为肾血肿。3例患者(7.8%)发生了造影剂肾病,其中2例同时有肾血肿。
对于有凝血功能障碍和血小板减少症且需要肾组织进行准确诊断的高风险患者,TJRB是一种相对安全有效的诊断工具。